TLR4 genotype and environmental LPS mediate RSV bronchiolitis through Th2 polarization

Journal of Clinical Investigation

Volumn 125, Issue 2, 2015, Pages 571-582

  Caballero, Mauricio T ^a,b   Serra, M Elina ^a,b   Acosta, Patricio L ^a,b,c   Marzec, Jacqui ^d   Gibbons, Luz ^e   Salim, Maximiliano ^b,f   Rodriguez, Andrea ^b,g   Reynaldi, Andrea ^b,h   Garcia, Alejandro ^b,h   Bado, Daniela ^b,h   Buchholz, Ursula J ⁱ   Hijano, Diego R ^a,b,j   Coviello, Silvina ^a,b   Newcomb, Dawn ^j   Bellabarba, Miguel ^b,h   Ferolla, Fausto M ^a,b,c   Libster, Romina ^a,b,c,j   Berenstein, Ada ^b   Siniawaski, Susana ^b   Blumetti, Valeria ^k   Echavarria, Marcela ^c,l   Pinto, Leonardo ^a,m   Lawrence, Andrea ^j   Ossorio, M Fabiana ⁿ   Grosman, Arnoldo ^o   Mateu, Cecilia G ^a,b,c   Bayle, Carola ^p   Dericco, Alejandra ^p   Pellegrini, Mariana ^p   Igarza, Ignacio ^p   Repetto, Horacio A ^p   Grimaldi, Luciano Alva ^q   Gudapati, Prathyusha ^j   Polack, Norberto R ^b,h   Althabe, Fernando ^e   Shi, Min ^d   Ferrero, Fernando ⁿ   Bergel, Eduardo ^e   Stein, Renato T ^a,m   Peebles, R Stokes ^j   Boothby, Mark ^j   Kleeberger, Steven R ^d   Polack, Fernando P ^a,b,j   more..

^a Alianza INFANT Argentina Brasil   (Argentina)

^b Fundacion INFANT   (Argentina)

^c Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^e INSTITUTE FOR CLINICAL EFFECTIVENESS AND HEALTH POLICY   (Argentina)

^f Hospital Evita Pueblo   (Argentina)

^g Hospital Mi Pueblo   (Argentina)

^h HOSPITAL FRANCÉS   (Argentina)

ⁱ NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^j VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^k Swiss Medical   (Argentina)

^l CEMIC   (Argentina)

^m PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

ⁿ HOSPITAL GENERAL DE NIÑOS PEDRO DE ELIZALDE   (Argentina)

^o HOSPITAL ESPAÑOL   (Argentina)

^p HOSPITAL NACIONAL PROFESOR ALEJANDRO POSADAS   (Argentina)

^q Hospital Zonal General de Agudos Lucio Meléndez   (Argentina)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; GATA3 PROTEIN, HUMAN; GATA3 PROTEIN, MOUSE; IFNG PROTEIN, HUMAN; IL4 PROTEIN, HUMAN; T BOX TRANSCRIPTION FACTOR; T-BOX TRANSCRIPTION FACTOR TBX21; TLR4 PROTEIN, HUMAN; TLR4 PROTEIN, MOUSE;

ARTICLE; BRONCHIOLITIS; CHILD; DISEASE SEVERITY; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; GENOTYPE; HEREDITY; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; INFANT; MAJOR CLINICAL STUDY; NONHUMAN; NOSE SECRETION; PATHOGENESIS; POLARIZATION; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; ADVERSE EFFECTS; ANIMAL; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MODEL; FEMALE; GENETICS; IMMUNOLOGY; MALE; MOUSE; MULTICENTER STUDY; NEWBORN; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; TH2 CELL; VIRAL BRONCHIOLITIS;

ANIMALS; BRONCHIOLITIS, VIRAL; DISEASE MODELS, ANIMAL; ENVIRONMENTAL EXPOSURE; FEMALE; GATA3 TRANSCRIPTION FACTOR; GENOTYPE; HUMANS; INFANT; INFANT, NEWBORN; INTERFERON-GAMMA; INTERLEUKIN-4; LIPOPOLYSACCHARIDES; MALE; MICE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; T-BOX DOMAIN PROTEINS; TH2 CELLS; TOLL-LIKE RECEPTOR 4;

EID: 84926427192     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI75183     Document Type: Article

References (60)

1. Collins PL, Chanock RM, Murphy BR. Respiratory syncytial virus disease. In: Knipe D, et al., eds. Fields Virology. 4th ed. Vol. 1. Philadelphia, Pennsylvania, USA: Lippincott Williams & Wilkins; 2001:1443-1486.
2. Simoes EA. Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr. 2003;143(5 suppl):S118-S126.
3. Ferolla FM, et al. Macronutrients during pregnancy and life-threatening respiratory syncytial virus infections in children. Am J Respir Crit Care Med. 2013;187(9):983-990.
4. Hoffman SJ, Laham FR, Polack FP. Mechanisms of illness during respiratory syncytial virus infection: the lungs, the virus and the immune response. Microbes Infect. 2004;6(8):767-772.
5. Karron RA, et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis. 2005;191(7):1093-1104.
6. Hull J, Thomson A, Kwiatkowski D. Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. Thorax. 2000;55(12):1023-1027.
7. Openshaw PJ. Immunity and immunopathology to respiratory syncytial virus. The mouse model. Am J Respir Crit Care Med. 1995;152(4 pt 2):S59-62.
8. McNamara PS, Flanagan BF, Baldwin LM, Newland P, Hart CA, Smyth RL. Interleukin 9 production in the lungs of infants with severe respiratory syncytial virus bronchiolitis. Lancet. 2004;363(9414):1031-1037.
9. Hoebee B, et al. Association of severe respiratory syncytial virus bronchiolitis with interleukin-4 and interleukin-4 receptor α polymorphisms. J Infect Dis. 2003;187(1):2-11.
10. Webb DC, Mahalingam S, Cai Y, Matthaei KI, Donaldson DD, Foster PS. Antigen-specific production of interleukin (IL)-13 and IL-5 cooperate to mediate IL-4Rα-independent airway hyperreactivity. Eur J Immunol. 2003;33(12):3377-3385.
11. Legg JP, Hussain IR, Warner JA, Johnston SL, Warner JO. Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med. 2003;168(6):633-639.
12. Kurt-Jones EA, et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol. 2000;1(5):398-401.
13. Haynes LM, Moore DD, Kurt-Jones EA, Finberg RW, Anderson LJ, Tripp RA. Involvement of tolllike receptor 4 in innate immunity to respiratory syncytial virus. J Virol. 2001;75(22):10730-10737.
14. Ehl S, et al. The role of Toll-like receptor 4 versus interleukin-12 in immunity to respiratory syncytial virus. Eur J Immunol. 2004;34(4):1146-1153.
15. Tal G, et al. Association between common Toll-like receptor 4 mutations and severe respiratory syncytial virus disease. J Infect Dis. 2004;189(11):2057-2063.
16. Inoue Y, et al. CD14-550 C/T, which is related to the serum level of soluble CD14, is associated with the development of respiratory syncytial virus bronchiolitis in the Japanese population. J Infect Dis. 2007;195(11):1618-1624.
17. Puthothu B, Forster J, Heinzmann A, Krueger M. TLR-4 and CD14 polymorphisms in respiratory syncytial virus associated disease. Dis Markers. 2006;22(5-6):303-308.
18. Paulus SC, Hirschfeld AF, Victor RE, Brunstein J, Thomas E, Turvey SE. Common human Toll-like receptor 4 polymorphisms - role in susceptibility to respiratory syncytial virus infection and functional immunological relevance. Clin Immunol. 2007;123(3):252-257.
19. Kresfelder TL, Janssen R, Bont L, Pretorius M, Venter M. Confirmation of an association between single nucleotide polymorphisms in the VDR gene with respiratory syncytial virus related disease in South African children. J Med Virol. 2011;83(10):1834-1840.
20. Smit LA, et al. CD14 and toll-like receptor gene polymorphisms, country living, and asthma in adults. Am J Respir Crit Care Med. 2009;179(5):363-368.
21. Martinez FD. Gene-environment interactions in asthma: with apologies to William of Ockham. Proc Am Thorac Soc. 2007;4(1):26-31.
22. Arbour NC, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet. 2000;25(2):187-191.
23. Braun-Fahrlander C, et al. Environmental exposure to endotoxin and its relation to asthma in school-age children. N Engl J Med. 2002;347(12):869-877.
24. Larsson L, et al. Identification of bacterial and fungal components in tobacco and tobacco smoke. Tob Induc Dis. 2008;4:4.
25. Malley R, et al. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci U S A. 2003;100(4):1966-1971.
26. Wang X, et al. Toll-like receptor 4 mediates innate immune responses to Haemophilus influenzae infection in mouse lung. J Immunol. 2002;168(2):810-815.
27. Hassan F, Ren D, Zhang W, Merkel TJ, Gu XX. Moraxella catarrhalis activates murine macrophages through multiple toll like receptors and has reduced clearance in lungs from TLR4 mutant mice. PLoS One. 2012;7(5):e37610.
28. Waser M, et al. Determinants of endotoxin levels in living environments of farmers' children and their peers from rural areas. Clin Exp Allergy. 2004;34(3):389-397.
29. Thorne PS, Cohn RD, Mav D, Arbes SJ, Zeldin DC. Predictors of endotoxin levels in U. S.housing. Environ Health Perspect. 2009;117(5):763-771.
30. Ferwerda B, et al. TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans. Proc Natl Acad Sci U S A. 2007;104(42):16645-16650.
31. Simpson A, et al. Endotoxin exposure, CD14, and allergic disease: an interaction between genes and the environment. Am J Respir Crit Care Med. 2006;174(4):386-392.
32. Miller SI, Ernst RK, Bader MW. LPS, TLR4 and infectious disease diversity. Nat Rev Microbiol. 2005;3(1):36-46.
33. Perros F, Lambrecht BN, Hammad H. TLR4 signalling in pulmonary stromal cells is critical for inflammation and immunity in the airways. Respir Res. 2011;12:125.
34. Eisenbarth SC, Piggott DA, Huleatt JW, Visintin I, Herrick CA, Bottomly K. Lipopolysaccharide-enhanced, toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen. J Exp Med. 2002;196(12):1645-1651.
35. Glimcher LH. Trawling for treasure: tales of T-bet. Nat Immunol. 2007;8(5):448-450.
36. Zhu J, Yamane H, Cote-Sierra J, Guo L, Paul WE. GATA-3 promotes Th2 responses through three different mechanisms: induction of Th2 cytokine production, selective growth of Th2 cells and inhibition of Th1 cell-specific factors. Cell Res. 2006;16(1):3-10.
37. Robinson DS, O'Garra A. Further checkpoints in Th1 development. Immunity. 2002;16(6):755-758.
38. Kaplan MH, Schindler U, Smiley ST, Grusby MJ. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity. 1996;4(3):313-319.
39. Wright PF, et al. Illness severity, viral shedding, and antibody responses in infants hospitalized with bronchiolitis caused by respiratory syncytial virus. J Infect Dis. 2002;185(8):1011-1018.
40. Corneli HM, et al. A multicenter, randomized, controlled trial of dexamethasone for bronchiolitis. N Engl J Med. 2007;357(4):331-339.
41. Sheeran P, et al. Elevated cytokine concentrations in the nasopharyngeal and tracheal secretions of children with respiratory syncytial virus disease. Pediatr Infect Dis J. 1999;18(2):115-122.
42. Welliver TP, et al. Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J Infect Dis. 2007;195(8):1126-1136.
43. Laham FR, et al. Differential production of inflammatory cytokines in primary infection with human metapneumovirus and with other common respiratory viruses of infancy. J Infect Dis. 2004;189(11):2047-2056.
44. Ripple MJ, et al. Immunomodulation with IL-4R α antisense oligonucleotide prevents respiratory syncytial virus-mediated pulmonary disease. J Immunol. 2010;185(8):4804-4811.
45. Perumal NB, Kaplan MH. Regulating Il9 transcription in T helper cells. Trends Immunol. 2011;32(4):146-150.
46. Walker JA, Barlow JL, McKenzie AN. Innate lymphoid cells-how did we miss them? Nat Rev Immunol. 2013;13(2):75-87.
47. Marr N, Turvey SE. Role of human TLR4 in respiratory syncytial virus-induced NF-κB activation, viral entry and replication. Innate Immun. 2012;18(6):856-865.
48. Hall CB, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360(6):588-598.
49. [No authors listed]. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics. 1998;102(3 pt 1):531-537.
50. Awomoyi AA, et al. Association of TLR4 polymorphisms with symptomatic respiratory syncytial virus infection in high-risk infants and young children. J Immunol. 2007;179(5):3171-3177.
51. Wenzel S, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368(26):2455-2466.
52. Hall CB. Respiratory syncytial virus in young children. Lancet. 2010;375(9725):1500-1502.
53. Nair H, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375(9725):1545-1555.
54. Prince LS, Dieperink HI, Okoh VO, Fierro-Perez GA, Lallone RL. Toll-like receptor signaling inhibits structural development of the distal fetal mouse lung. Dev Dyn. 2005;233(2):553-561.
55. Soutiere SE, Tankersley CG, Mitzner W. Differences in alveolar size in inbred mouse strains. Respir Physiol Neurobiol. 2004;140(3):283-291.
56. Gereda JE, et al. Relation between house-dust endotoxin exposure, type 1 T-cell development, and allergen sensitisation in infants at high risk of asthma. Lancet. 2000;355(9216):1680-1683.
57. Gereda JE, Klinnert MD, Price MR, Leung DY, Liu AH. Metropolitan home living conditions associated with indoor endotoxin levels. J Allergy Clin Immunol. 2001;107(5):790-796.
58. Rosenthal N, Schwartz RS. In search of perverse polymorphisms. N Engl J Med. 1998;338(2):122-124.
59. Lukacs NW, et al. Differential immune responses and pulmonary pathophysiology are induced by two different strains of respiratory syncytial virus. Am J Pathol. 2006;169(3):977-986.
60. Delgado MF, et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med. 2009;15(1):34-41.